JOHN BELMONT to Genetic Vectors
This is a "connection" page, showing publications JOHN BELMONT has written about Genetic Vectors.
Connection Strength
0.572
-
Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. Blood. 1992 Mar 15; 79(6):1393-9.
Score: 0.074
-
Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector. Hum Gene Ther. 1991; 2(4):307-15.
Score: 0.069
-
Murine leukemia inhibitory factor enhances retroviral-vector infection efficiency of hematopoietic progenitors. Blood. 1990 Sep 15; 76(6):1098-103.
Score: 0.067
-
Stable RNA secondary structure in a retroviral vector insert terminates reverse transcriptase elongation in vitro but not in cultured cells. Hum Gene Ther. 1990; 1(3):269-76.
Score: 0.064
-
Expression vectors for human adenosine deaminase gene therapy. Genome. 1989; 31(2):832-9.
Score: 0.060
-
In vivo marking of spontaneous or vaccine-induced fibrosarcomas in the domestic house cat, using an adenoviral vector containing a bifunctional fusion protein, GAL-TEK. Hum Gene Ther. 1995 Sep; 6(9):1215-23.
Score: 0.024
-
Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther. 1995 May; 2(3):181-6.
Score: 0.023
-
A new family of murine retroviral vectors with extended multiple cloning sites for gene insertion. Hum Gene Ther. 1994 Mar; 5(3):307-12.
Score: 0.021
-
Leukemia inhibitory factor improves survival of retroviral vector-infected hematopoietic stem cells in vitro, allowing efficient long-term expression of vector-encoded human adenosine deaminase in vivo. J Exp Med. 1991 Oct 01; 174(4):837-45.
Score: 0.018
-
Stimulation of retroviral vector infection of murine hematopoietic progenitors. Int J Cell Cloning. 1991 Sep; 9(5):491-502.
Score: 0.018
-
Characterization of recombinant helper retroviruses from Moloney-based vectors in ecotropic and amphotropic packaging cell lines. Virology. 1991 Feb; 180(2):849-52.
Score: 0.017
-
Effects of leukemia inhibitory factor (LIF) on gene transfer efficiency into murine hematolymphoid progenitors. Adv Exp Med Biol. 1991; 292:131-8.
Score: 0.017
-
Human adenosine deaminase expression in mice. Blood. 1990 May 15; 75(10):2085-92.
Score: 0.016
-
Expression of human adenosine deaminase in murine hematopoietic cells. Mol Cell Biol. 1988 Dec; 8(12):5116-25.
Score: 0.015
-
Human gene expression in murine hemopoietic cells in vivo. Adv Exp Med Biol. 1988; 241:123-7.
Score: 0.014
-
Expression of human adenosine deaminase in murine haematopoietic progenitor cells following retroviral transfer. Nature. 1986 Jul 24-30; 322(6077):385-7.
Score: 0.013
-
Towards gene therapy for adenosine deaminase deficiency. Ann Clin Res. 1986; 18(5-6):322-6.
Score: 0.012
-
Gene replacement therapy for inborn errors of purine metabolism. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:1065-71.
Score: 0.012
-
Expression of human CD18 in murine granulocytes and improved efficiency for infection of deficient human lymphoblasts. Hum Gene Ther. 1993 Feb; 4(1):25-34.
Score: 0.005
-
Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45.
Score: 0.005
-
Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells. Hum Gene Ther. 1991; 2(3):203-13.
Score: 0.004
-
Gene therapy: a new approach for the treatment of genetic disorders. Clin Pharmacol Ther. 1990 Jan; 47(1):1-11.
Score: 0.004